Morgan Stanley
MS · NYSE
$206.58+$42.2625.72%
$207.20+$0.620.30%
MS · NYSE
Morgan Stanley is a global financial-services company serving corporations, institutions, governments, investment funds, high-net-worth individuals, and retail investors. Its principal businesses are Institutional Securities, which provides investment banking, sales and trading, and related advisory services; Wealth Management, which provides brokerage, financial planning, lending, and investment advice; and Investment Management, which manages assets for institutional and individual clients. The supplied evidence does not provide current segment revenue contributions or client-asset figures. Morgan Stanley reported fiscal-year 2025 net income of $16.9 billion, up from $13.4 billion in fiscal 2024, although the supplied revenue figures are unavailable.
Morgan Stanley fell 5.12%, from $217.72 to $206.58 over the supplied week, with the decline concentrated in the final session. The stock had already eased from $217.72 on September 4 to $214.38 on September 11, then dropped 3.64% on September 14 on volume of 7.50 million shares, well above the roughly 3.1 million to 4.5 million shares in the preceding sessions. The supplied evidence does not identify a company-specific earnings release, guidance change, or named analyst action explaining the selloff. Coverage instead included discussion that the shares looked fairly priced as a crash warning loomed and that fund momentum may have shifted, but neither snippet establishes causation. No broader market benchmark or macro catalyst was supplied.
Morgan Stanley rose $2.92, or 1.37%, from $213.32 to $216.24 over the reported week. The stock initially weakened, falling to $211.04 on September 1 from $213.32 on August 31, before recovering modestly to $211.82 the next day. It then advanced sharply to $217.15 on September 3 and $217.72 on September 4, gaining more than 2.7% from the weekly low. By September 8, it had given back part of that rally, closing at $216.24. The supplied evidence identifies no company-specific announcement or attributable analyst action driving the move. Relevant coverage instead discussed Morgan Stanley’s relative performance and a more significant dip than the broader market, leaving market and trading factors as the clearest explanation.
Morgan Stanley rose $2.29, or 1.07%, from $214.86 to $217.15 over the week, despite a sharp early pullback. The stock fell to $213.32 on Monday and $211.04 on Tuesday, with Zacks attributing Tuesday’s 1.07% decline to weakness greater than the broader market. It recovered modestly on Wednesday before surging 2.51% on Thursday to finish at the weekly high. No company-specific announcement or analyst action in the supplied evidence clearly explains the reversal. The week’s backdrop included a reported ETF inflow involving MS and a Zacks industry view that investment banks could benefit from stronger deal activity, trading and technology spending, but the evidence does not establish either as the direct cause of Thursday’s rally.
Morgan Stanley rose $7.41, or 3.57%, over the week, closing at $214.86 versus $207.45. It started near $214.20 on Aug. 21 and slipped marginally Monday to $214.08, then advanced 1.26% Tuesday to $216.77 before giving back most of that gain Wednesday, falling to $214.08. Thursday brought a modest recovery to $214.86. No company-specific announcement or attributable analyst target change was supplied to explain the day-to-day pattern. Positive background coverage highlighted Morgan Stanley’s strong first-half 2026 results, improving diversification and investment-banking recovery, while broader trading was cautious ahead of Nvidia’s earnings as Treasury yields rose. This mix is consistent with a firm-specific positive bias despite muted market conditions.
Morgan Stanley fell 5.01% over the week, from $218.38 to $207.45. The stock initially stabilized, rising to $218.21 on Monday after the prior Friday’s modest decline, then slipped to $217.55 on Tuesday. Selling accelerated Wednesday, when it dropped to $214.23 on 4.91 million shares, and intensified Thursday with a further decline to $207.45 on 4.88 million shares. The supplied evidence identifies no company-specific earnings release, guidance change, transaction, or analyst action dated during the week that explains the reversal and late-week volume increase. Articles concerning a former-advisor lawsuit, a preferred security’s yield, an upcoming co-president appearance, and Morgan Stanley’s AI power-gap research do not state that they drove the common stock. No market benchmark or sector catalyst is provided.
Morgan Stanley rose $4.10, or 1.94%, from $211.23 to $215.33 over the week. Trading was volatile rather than steadily upward: the stock jumped $5.81 on August 4 on volume of 8.9 million shares, added another $1.23 on August 5, then gave back $4.52 on August 6. It recovered $2.58 on August 7 before slipping $1.00 on August 10. The supplied evidence does not identify company-specific news that explains the net gain or the reversals. An Eaton Vance item about redeeming remaining auction preferred shares is company-related but provides no stated financial impact on Morgan Stanley. Broader market context is also not supplied.
Morgan Stanley rose $5.46, or 2.58%, from $211.58 to $217.04 over the week. Trading was volatile: the stock fell $8.45 on July 29, then recovered $6.93 on July 30 and added modestly on July 31 and August 3 before jumping $5.81 on August 4. The final-day advance came with volume of 8.93 million shares, well above the prior session’s 4.98 million. The supplied evidence does not identify a dated company-specific catalyst for the move. Morgan Stanley’s new Ethereum and Solana ETFs and UBS’s higher target are relevant investor themes, but neither is explicitly tied to a trading day. The stock therefore appears to have moved mainly without documented company-specific news.
